English
简体中文
Total: £ 56.28
Published Date: 2025-12-23 | Pages: 74 | Tables: 79 | Pharma & Healthcare
The global market for CAR-T Therapy for Hematological Cancer was valued at US$ 4087 million in the year 2024 and is projected to reach a revised size of US$ 21680 million by 2031, growing at a CAGR of 26.0% during the forecast period.
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a cutting-edge immunotherapy for hematological cancers, involving the genetic modification of a patient’s T cells to express synthetic receptors targeting specific antigens on cancer cells. These engineered T cells are expanded in the lab and reintroduced into the patient, where they can recognize and destroy cancerous cells with high specificity. Key features include its remarkable efficacy in treating certain blood cancers like B-cell lymphomas, leukemias, and multiple myeloma, particularly in patients with relapsed or refractory disease, and its potential for long-term remission. CAR-T therapy is primarily applied in advanced hematological malignancies and is being explored for broader indications through ongoing clinical trials. Despite its promise, challenges such as high cost, manufacturing complexity, and management of severe side effects like cytokine release syndrome (CRS) remain areas of active research.
North American market for CAR-T Therapy for Hematological Cancer is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for CAR-T Therapy for Hematological Cancer is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for CAR-T Therapy for Hematological Cancer in Lymphoma is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of CAR-T Therapy for Hematological Cancer include Novartis, Gilead Sciences, Bristol-Myers Squibb, J&J, JW Therapeutics, FOSUNKite, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for CAR-T Therapy for Hematological Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CAR-T Therapy for Hematological Cancer.
The CAR-T Therapy for Hematological Cancer market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global CAR-T Therapy for Hematological Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CAR-T Therapy for Hematological Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Gilead Sciences
Bristol-Myers Squibb
J&J
JW Therapeutics
FOSUNKite
Segment by Type
Target: CD19
Target: BCMA
Others
Segment by Application
Lymphoma
Multiple Myeloma
Leukemia
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CAR-T Therapy for Hematological Cancer company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CAR-T Therapy for Hematological Cancer Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Target: CD19
1.2.3 Target: BCMA
1.2.4 Others
1.3 Market by Application
1.3.1 Global CAR-T Therapy for Hematological Cancer Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Lymphoma
1.3.3 Multiple Myeloma
1.3.4 Leukemia
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global CAR-T Therapy for Hematological Cancer Market Perspective (2020-2031)
2.2 Global CAR-T Therapy for Hematological Cancer Growth Trends by Region
2.2.1 Global CAR-T Therapy for Hematological Cancer Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 CAR-T Therapy for Hematological Cancer Historic Market Size by Region (2020-2025)
2.2.3 CAR-T Therapy for Hematological Cancer Forecasted Market Size by Region (2026-2031)
2.3 CAR-T Therapy for Hematological Cancer Market Dynamics
2.3.1 CAR-T Therapy for Hematological Cancer Industry Trends
2.3.2 CAR-T Therapy for Hematological Cancer Market Drivers
2.3.3 CAR-T Therapy for Hematological Cancer Market Challenges
2.3.4 CAR-T Therapy for Hematological Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CAR-T Therapy for Hematological Cancer Players by Revenue
3.1.1 Global Top CAR-T Therapy for Hematological Cancer Players by Revenue (2020-2025)
3.1.2 Global CAR-T Therapy for Hematological Cancer Revenue Market Share by Players (2020-2025)
3.2 Global Top CAR-T Therapy for Hematological Cancer Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by CAR-T Therapy for Hematological Cancer Revenue
3.4 Global CAR-T Therapy for Hematological Cancer Market Concentration Ratio
3.4.1 Global CAR-T Therapy for Hematological Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CAR-T Therapy for Hematological Cancer Revenue in 2024
3.5 Global Key Players of CAR-T Therapy for Hematological Cancer Head office and Area Served
3.6 Global Key Players of CAR-T Therapy for Hematological Cancer, Product and Application
3.7 Global Key Players of CAR-T Therapy for Hematological Cancer, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 CAR-T Therapy for Hematological Cancer Breakdown Data by Type
4.1 Global CAR-T Therapy for Hematological Cancer Historic Market Size by Type (2020-2025)
4.2 Global CAR-T Therapy for Hematological Cancer Forecasted Market Size by Type (2026-2031)
5 CAR-T Therapy for Hematological Cancer Breakdown Data by Application
5.1 Global CAR-T Therapy for Hematological Cancer Historic Market Size by Application (2020-2025)
5.2 Global CAR-T Therapy for Hematological Cancer Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America CAR-T Therapy for Hematological Cancer Market Size (2020-2031)
6.2 North America CAR-T Therapy for Hematological Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America CAR-T Therapy for Hematological Cancer Market Size by Country (2020-2025)
6.4 North America CAR-T Therapy for Hematological Cancer Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CAR-T Therapy for Hematological Cancer Market Size (2020-2031)
7.2 Europe CAR-T Therapy for Hematological Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe CAR-T Therapy for Hematological Cancer Market Size by Country (2020-2025)
7.4 Europe CAR-T Therapy for Hematological Cancer Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CAR-T Therapy for Hematological Cancer Market Size (2020-2031)
8.2 Asia-Pacific CAR-T Therapy for Hematological Cancer Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific CAR-T Therapy for Hematological Cancer Market Size by Region (2020-2025)
8.4 Asia-Pacific CAR-T Therapy for Hematological Cancer Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CAR-T Therapy for Hematological Cancer Market Size (2020-2031)
9.2 Latin America CAR-T Therapy for Hematological Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America CAR-T Therapy for Hematological Cancer Market Size by Country (2020-2025)
9.4 Latin America CAR-T Therapy for Hematological Cancer Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size (2020-2031)
10.2 Middle East & Africa CAR-T Therapy for Hematological Cancer Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size by Country (2020-2025)
10.4 Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis CAR-T Therapy for Hematological Cancer Introduction
11.1.4 Novartis Revenue in CAR-T Therapy for Hematological Cancer Business (2020-2025)
11.1.5 Novartis Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Details
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences CAR-T Therapy for Hematological Cancer Introduction
11.2.4 Gilead Sciences Revenue in CAR-T Therapy for Hematological Cancer Business (2020-2025)
11.2.5 Gilead Sciences Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Details
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb CAR-T Therapy for Hematological Cancer Introduction
11.3.4 Bristol-Myers Squibb Revenue in CAR-T Therapy for Hematological Cancer Business (2020-2025)
11.3.5 Bristol-Myers Squibb Recent Development
11.4 J&J
11.4.1 J&J Company Details
11.4.2 J&J Business Overview
11.4.3 J&J CAR-T Therapy for Hematological Cancer Introduction
11.4.4 J&J Revenue in CAR-T Therapy for Hematological Cancer Business (2020-2025)
11.4.5 J&J Recent Development
11.5 JW Therapeutics
11.5.1 JW Therapeutics Company Details
11.5.2 JW Therapeutics Business Overview
11.5.3 JW Therapeutics CAR-T Therapy for Hematological Cancer Introduction
11.5.4 JW Therapeutics Revenue in CAR-T Therapy for Hematological Cancer Business (2020-2025)
11.5.5 JW Therapeutics Recent Development
11.6 FOSUNKite
11.6.1 FOSUNKite Company Details
11.6.2 FOSUNKite Business Overview
11.6.3 FOSUNKite CAR-T Therapy for Hematological Cancer Introduction
11.6.4 FOSUNKite Revenue in CAR-T Therapy for Hematological Cancer Business (2020-2025)
11.6.5 FOSUNKite Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global CAR-T Therapy for Hematological Cancer Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Target: CD19
Table 3. Key Players of Target: BCMA
Table 4. Key Players of Others
Table 5. Global CAR-T Therapy for Hematological Cancer Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global CAR-T Therapy for Hematological Cancer Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global CAR-T Therapy for Hematological Cancer Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global CAR-T Therapy for Hematological Cancer Market Share by Region (2020-2025)
Table 9. Global CAR-T Therapy for Hematological Cancer Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global CAR-T Therapy for Hematological Cancer Market Share by Region (2026-2031)
Table 11. CAR-T Therapy for Hematological Cancer Market Trends
Table 12. CAR-T Therapy for Hematological Cancer Market Drivers
Table 13. CAR-T Therapy for Hematological Cancer Market Challenges
Table 14. CAR-T Therapy for Hematological Cancer Market Restraints
Table 15. Global CAR-T Therapy for Hematological Cancer Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global CAR-T Therapy for Hematological Cancer Market Share by Players (2020-2025)
Table 17. Global Top CAR-T Therapy for Hematological Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CAR-T Therapy for Hematological Cancer as of 2024)
Table 18. Ranking of Global Top CAR-T Therapy for Hematological Cancer Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by CAR-T Therapy for Hematological Cancer Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of CAR-T Therapy for Hematological Cancer, Headquarters and Area Served
Table 21. Global Key Players of CAR-T Therapy for Hematological Cancer, Product and Application
Table 22. Global Key Players of CAR-T Therapy for Hematological Cancer, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global CAR-T Therapy for Hematological Cancer Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global CAR-T Therapy for Hematological Cancer Revenue Market Share by Type (2020-2025)
Table 26. Global CAR-T Therapy for Hematological Cancer Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global CAR-T Therapy for Hematological Cancer Revenue Market Share by Type (2026-2031)
Table 28. Global CAR-T Therapy for Hematological Cancer Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global CAR-T Therapy for Hematological Cancer Revenue Market Share by Application (2020-2025)
Table 30. Global CAR-T Therapy for Hematological Cancer Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global CAR-T Therapy for Hematological Cancer Revenue Market Share by Application (2026-2031)
Table 32. North America CAR-T Therapy for Hematological Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America CAR-T Therapy for Hematological Cancer Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America CAR-T Therapy for Hematological Cancer Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe CAR-T Therapy for Hematological Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe CAR-T Therapy for Hematological Cancer Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe CAR-T Therapy for Hematological Cancer Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific CAR-T Therapy for Hematological Cancer Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific CAR-T Therapy for Hematological Cancer Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific CAR-T Therapy for Hematological Cancer Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America CAR-T Therapy for Hematological Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America CAR-T Therapy for Hematological Cancer Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America CAR-T Therapy for Hematological Cancer Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size by Country (2026-2031) & (US$ Million)
Table 47. Novartis Company Details
Table 48. Novartis Business Overview
Table 49. Novartis CAR-T Therapy for Hematological Cancer Product
Table 50. Novartis Revenue in CAR-T Therapy for Hematological Cancer Business (2020-2025) & (US$ Million)
Table 51. Novartis Recent Development
Table 52. Gilead Sciences Company Details
Table 53. Gilead Sciences Business Overview
Table 54. Gilead Sciences CAR-T Therapy for Hematological Cancer Product
Table 55. Gilead Sciences Revenue in CAR-T Therapy for Hematological Cancer Business (2020-2025) & (US$ Million)
Table 56. Gilead Sciences Recent Development
Table 57. Bristol-Myers Squibb Company Details
Table 58. Bristol-Myers Squibb Business Overview
Table 59. Bristol-Myers Squibb CAR-T Therapy for Hematological Cancer Product
Table 60. Bristol-Myers Squibb Revenue in CAR-T Therapy for Hematological Cancer Business (2020-2025) & (US$ Million)
Table 61. Bristol-Myers Squibb Recent Development
Table 62. J&J Company Details
Table 63. J&J Business Overview
Table 64. J&J CAR-T Therapy for Hematological Cancer Product
Table 65. J&J Revenue in CAR-T Therapy for Hematological Cancer Business (2020-2025) & (US$ Million)
Table 66. J&J Recent Development
Table 67. JW Therapeutics Company Details
Table 68. JW Therapeutics Business Overview
Table 69. JW Therapeutics CAR-T Therapy for Hematological Cancer Product
Table 70. JW Therapeutics Revenue in CAR-T Therapy for Hematological Cancer Business (2020-2025) & (US$ Million)
Table 71. JW Therapeutics Recent Development
Table 72. FOSUNKite Company Details
Table 73. FOSUNKite Business Overview
Table 74. FOSUNKite CAR-T Therapy for Hematological Cancer Product
Table 75. FOSUNKite Revenue in CAR-T Therapy for Hematological Cancer Business (2020-2025) & (US$ Million)
Table 76. FOSUNKite Recent Development
Table 77. Research Programs/Design for This Report
Table 78. Key Data Information from Secondary Sources
Table 79. Key Data Information from Primary Sources
Table 80. Authors List of This Report
List of Figures
Figure 1. CAR-T Therapy for Hematological Cancer Picture
Figure 2. Global CAR-T Therapy for Hematological Cancer Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global CAR-T Therapy for Hematological Cancer Market Share by Type: 2024 VS 2031
Figure 4. Target: CD19 Features
Figure 5. Target: BCMA Features
Figure 6. Others Features
Figure 7. Global CAR-T Therapy for Hematological Cancer Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global CAR-T Therapy for Hematological Cancer Market Share by Application: 2024 VS 2031
Figure 9. Lymphoma Case Studies
Figure 10. Multiple Myeloma Case Studies
Figure 11. Leukemia Case Studies
Figure 12. CAR-T Therapy for Hematological Cancer Report Years Considered
Figure 13. Global CAR-T Therapy for Hematological Cancer Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global CAR-T Therapy for Hematological Cancer Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global CAR-T Therapy for Hematological Cancer Market Share by Region: 2024 VS 2031
Figure 16. Global CAR-T Therapy for Hematological Cancer Market Share by Players in 2024
Figure 17. Global CAR-T Therapy for Hematological Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 18. The Top 10 and 5 Players Market Share by CAR-T Therapy for Hematological Cancer Revenue in 2024
Figure 19. North America CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America CAR-T Therapy for Hematological Cancer Market Share by Country (2020-2031)
Figure 21. United States CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe CAR-T Therapy for Hematological Cancer Market Share by Country (2020-2031)
Figure 25. Germany CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific CAR-T Therapy for Hematological Cancer Market Share by Region (2020-2031)
Figure 33. China CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America CAR-T Therapy for Hematological Cancer Market Share by Country (2020-2031)
Figure 41. Mexico CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa CAR-T Therapy for Hematological Cancer Market Share by Country (2020-2031)
Figure 45. Turkey CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE CAR-T Therapy for Hematological Cancer Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Novartis Revenue Growth Rate in CAR-T Therapy for Hematological Cancer Business (2020-2025)
Figure 49. Gilead Sciences Revenue Growth Rate in CAR-T Therapy for Hematological Cancer Business (2020-2025)
Figure 50. Bristol-Myers Squibb Revenue Growth Rate in CAR-T Therapy for Hematological Cancer Business (2020-2025)
Figure 51. J&J Revenue Growth Rate in CAR-T Therapy for Hematological Cancer Business (2020-2025)
Figure 52. JW Therapeutics Revenue Growth Rate in CAR-T Therapy for Hematological Cancer Business (2020-2025)
Figure 53. FOSUNKite Revenue Growth Rate in CAR-T Therapy for Hematological Cancer Business (2020-2025)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
